Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor

The cytokines that regulate angiogenesis in normal and malignant prostate tissue are not well studied. Using an RT‐PCR‐based screen, we observed that cultured, low‐passage normal human prostate epithelial cells (PrECs) express a variety of cytokines which have been shown to have angiogenic and/or endothelial cell–activating properties in various systems. These include vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF), transforming growth factor‐α (TGF‐α), transforming growth factor‐β (TGF‐β), interleukin‐8 (IL‐8), tumor necrosis factor‐α (TNF‐α), granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and granulocyte colony‐stimulating factor (G‐CSF). Expression of VEGF, bFGF, GM‐CSF, G‐CSF, TGF‐α and TNF‐α in these cells was confirmed by immuno‐histochemistry. Culture medium conditioned by normal human PrECs for periods of up to 96 hr were found to contain VEGF, GM‐CSF, G‐CSF, IL‐8, TGF‐β1 and TGF‐β2 but not TNF‐α or bFGF, as determined by ELISA. Of these, VEGF was by far the most prominently expressed angiogenic cytokine (approx. 2,500 pg/ml conditioned medium at 96 hr vs. 30 to 100 pg/ml conditioned medium for the other cytokines). PrEC‐conditioned medium induced an approximately 2‐fold stimulation of [3H]‐thymidine incorporation in cultured human umbilical cord endothelial cells (HUVECs) deprived of the endothelial growth factors VEGF and bFGF; this stimulation was abolished by neutralizing antibodies directed against VEGF but not bFGF, IL‐8, GM‐CSF or TNF‐α. VEGF expression by PrECs was not markedly altered by administration or deprivation of other angiogenic cytokines for which these cells have receptors, suggesting that there is not a hierarchy of cytokines controlling its expression; however, retinoic acid, a component of PrEC growth medium, was found to modestly suppress VEGF at physiological concentrations (0.1 ng/ml). These data suggest that normal PrECs express a variety of angiogenic cytokines, most prominently VEGF, to recruit a supporting vasculature, even in culture. Our data also suggest that the ability of malignant PrECs to stimulate angiogenesis may be intrinsic and does not need to be acquired during oncogenesis. Int. J. Cancer80:868–874, 1999. © 1999 Wiley‐Liss, Inc.

[1]  J. Isaacs,et al.  Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. , 1997, Cancer research.

[2]  H. Shepard,et al.  Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α , 1987, Nature.

[3]  K. Griffiths,et al.  Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. , 1996, British Journal of Cancer.

[4]  M. Klagsbrun,et al.  Regulators of angiogenesis. , 1991, Annual review of physiology.

[5]  P. Quesenberry,et al.  Expression and function of colony‐stimulating factors and their receptors in human prostate carcinoma cell lines , 1998, The Prostate.

[6]  R. Strieter,et al.  Interleukin-8 as a macrophage-derived mediator of angiogenesis. , 1992, Science.

[7]  K. Griffiths,et al.  Transforming growth factor beta I expression in benign and malignant prostatic tumors , 1994, The Prostate.

[8]  T. Stamey,et al.  Keratin immunoreactivity in the benign and neoplastic human prostate. , 1985, Cancer research.

[9]  H. Dvorak,et al.  Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. , 1995, The Journal of urology.

[10]  R. Derynck,et al.  Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. , 1986, Science.

[11]  J. Folkman,et al.  Angiogenesis is stimulated by a tumor‐derived endothelial cell growth factor , 1985, Journal of cellular biochemistry.

[12]  E. Sherwood,et al.  Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate. , 1992, Endocrinology.

[13]  A. Passaniti,et al.  Antiangiogenic effects of the quinoline-3-carboxamide linomide. , 1993, Cancer research.

[14]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[15]  J. Isaacs,et al.  Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. , 1996, Cancer research.

[16]  K. Thomas Vascular Endothelial Growth Factor, a Potent and Selective Angiogenic Agent (*) , 1996, The Journal of Biological Chemistry.

[17]  M. Kattan,et al.  Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[18]  A. Mantovani,et al.  Granulocyte- and granulocyte– macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate , 1989, Nature.

[19]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[20]  K. Benirschke,et al.  Fibroblast growth factor: its localization, purification, mode of action, and physiological significance. , 1975, Advances in metabolic disorders.

[21]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[22]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[23]  Itzhak D. Goldberg,et al.  Regulation of Angiogenesis , 1996, Experientia Supplementum.

[24]  A. Mantovani,et al.  In vitro and in vivo activation of endothelial cells by colony-stimulating factors. , 1991, The Journal of clinical investigation.

[25]  K. Griffiths,et al.  An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumors , 1993 .

[26]  R. Derynck,et al.  Transforming growth factor‐α , 1990, Molecular reproduction and development.